Form 8-K - Current report:
SEC Accession No. 0001140361-24-036392
Filing Date
2024-08-08
Accepted
2024-08-08 16:06:19
Documents
13
Period of Report
2024-08-08
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ny20022160x4_8k.htm   iXBRL 8-K 23299
  Complete submission text file 0001140361-24-036392.txt   159246

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA apri-20240808.xsd EX-101.SCH 3871
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE apri-20240808_lab.xml EX-101.LAB 21966
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apri-20240808_pre.xml EX-101.PRE 16048
16 EXTRACTED XBRL INSTANCE DOCUMENT ny20022160x4_8k_htm.xml XML 4217
Mailing Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022
Business Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022 (646) 293-2100
SEELOS THERAPEUTICS, INC. (Filer) CIK: 0001017491 (see all company filings)

EIN.: 870449967 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22245 | Film No.: 241188212
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)